文献速递新发突发、热带与寄生虫病

静脉青蒿琥酯治疗重症输入性疟疾:1391例患者的实施、疗效与安全性

Intravenous Artesunate for the Treatment of Severe Imported Malaria: Implementation, Efficacy, and Safety in 1391 Patients.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究在法国2011-2017年全国项目中前瞻性收集1391例接受青蒿琥酯治疗的重症输入性疟疾患者数据。青蒿琥酯使用比例从2011年9.9%升至2017年71.4%,死亡率为4.1%,治疗失败27例但未发现Kelch-13基因突变。主要不良事件为贫血136例、心脏事件24例和肝酶升高23例,特异性评估的98例亚组中迟发性溶血发生率为42.8%。

要点

  • 青蒿琥酯在法国迅速成为重症疟疾最常用治疗,2017年使用率达71.4%。
  • 死亡率4.1%,治疗失败27例,但未观察到Kelch-13基因突变。
  • 迟发性溶血发生率高(亚组42.8%),但未导致致命结局或后遗症。

核心结论

  • 青蒿琥酯在重症输入性疟疾中快速部署并显示出稳健的临床获益,尽管轻中度迟发性溶血发生率高。

研究设计与样本

  • 前瞻性收集法国2011-2017年全国项目中110个中心共1391例接受青蒿琥酯治疗患者的临床和流行病学特征。

主要发现

  • 青蒿琥酯成为法国重症疟疾最常用治疗,比例从2011年9.9%升至2017年71.4%。
  • 死亡率估计为4.1%,记录到27例治疗失败,但未观察到Kelch-13基因突变。
  • 主要不良事件为贫血136例、心脏事件24例(包括20例传导障碍和/或心律失常)和肝酶升高23例。
  • 在98例患者亚组中特异性评估的迟发性溶血发生率为42.8%,未与致命结局或后遗症相关。
  • 迟发性溶血在欧洲裔患者中的频率是非洲裔患者的两倍。

临床怎么用

  • 静脉青蒿琥酯可作为重症输入性疟疾的一线治疗,需监测迟发性溶血等不良事件。

局限性

  • 需进一步评估妊娠早期结局并收集罕见但可能严重的心脏不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous artesunate is the World Health Organization-recommended first-line treatment for severe malaria worldwide, but it is still not fully licensed in Europe. Observational studies documenting its safety and efficacy in imported malaria are thus essential. METHODS: We prospectively collected clinical and epidemiological features of 1391 artesunate-treated patients among 110 participant centers during the first 7 years (2011-2017) of a national program implemented by the French Drug Agency. RESULTS: Artesunate became the most frequent treatment for severe malaria in France, rising from 9.9% in 2011 to 71.4% in 2017. Mortality was estimated at 4.1%. Treatment failure was recorded in 27 patients, but mutations in the Kelch-13 gene were not observed. Main reported adverse events (AEs) were anemia (136 cases), cardiac events (24, including 20 episodes of conduction disorders and/or arrhythmia), and liver enzyme elevation (23). Mortality and AEs were similar in the general population and in people with human immunodeficiency virus, who were overweight, or were pregnant, but the only pregnant woman treated in the first trimester experimented a hemorrhagic miscarriage. The incidence of post-artesunate-delayed hemolysis (PADH) was 42.8% when specifically assessed in a 98-patient subgroup, but was not associated with fatal outcomes or sequelae. PADH was twice as frequent in patients of European compared with African origin. CONCLUSIONS: Artesunate was rapidly deployed and displayed a robust clinical benefit in patients with severe imported malaria, despite a high frequency of mild to moderate PADH. Further explorations in the context of importation should assess outcomes during the first trimester of pregnancy and collect rare but potentially severe cardiac AEs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Roussel C, Ndour PA, Kendjo E, et al. Intravenous Artesunate for the Treatment of Severe Imported Malaria: Implementation, Efficacy, and Safety in 1391 Patients. Clin Infect Dis. 2021. PMID: 33581690. doi:10.1093/cid/ciab133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。